Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
RY

NASDAQ · RYTM

Rhythm Pharmaceuticals, Inc.

Healthcare · Biotechnology

$90.77

Down-$1.68 (-1.82%)

Updated Oct 7, 2026, 4:31 AM

SID Score

3.9/10

Composite research score

Smart Money

58/100

Neutral

Market cap
7.84B
P/E ratio
-39.32
Dividend yield
0.00%
52-week range
$74.50 – $122.20
Volume
992.87K
Avg. volume
655.95K

Price performance · RYTM

RYTM price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

RYTM closed at $90.77 after 21 trading sessions, down 10.83% for the selected period.

Last close
$90.77
Period change
-10.83%
Period low
$90.77
Period high
$104.71
Daily close
View OHLC price history
RYTM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$92.55$94.47$90.07$90.77992.87K
Oct 5, 2026$93.95$94.408$89.53$92.451.03M
Oct 2, 2026$94.97$95.315$92.66$92.83503.54K
Oct 1, 2026$95.34$96.48$93.00$93.41850.61K
Sep 30, 2026$96.67$97.37$95.10$95.215737.18K
Sep 29, 2026$97.92$98.91$94.51$95.71810.86K
Sep 28, 2026$98.01$99.15$95.27$98.56897.36K
Sep 25, 2026$98.41$99.445$96.35$98.66864.26K
Sep 24, 2026$97.73$99.275$95.38$98.31730.81K
Sep 23, 2026$99.27$100.02$96.47$98.24696.41K
Sep 22, 2026$100.44$101.85$98.69$99.27499.89K
Sep 21, 2026$98.47$100.76$97.54$98.83613.6K
Sep 18, 2026$99.36$99.36$96.88$97.711.12M
Sep 17, 2026$101.17$102.00$98.80$99.02617.73K
Sep 16, 2026$97.69$100.85$97.06$98.01921.42K
Sep 15, 2026$101.66$101.66$96.14$96.77914.28K
Sep 14, 2026$105.27$105.93$101.09$102.44789.71K
Sep 11, 2026$102.96$106.57$102.245$104.71573.72K
Sep 10, 2026$99.88$102.89$99.88$102.20422.89K
Sep 9, 2026$100.23$101.77$99.8325$101.06482.25K
Sep 8, 2026$100.58$103.31$99.41$101.80513.05K

Latest RYTM news

The latest Smart Investors Daily articles mentioning RYTM.

Stock researchCompany · Overview

RYTM research

Overview

Company profile and research snapshot.

Company profile

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$130.20
Implied upside
—
Analysts
—
RYTM recent ratings
DateFirmRatingTarget
Aug 28, 2026Deutsche BankHold—
Aug 7, 2026JP MorganOverweight—
Aug 5, 2026CitizensMarket Outperform—
Aug 5, 2026RBC CapitalOutperform—
Aug 5, 2026CitigroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

-- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) --BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Health Canada has approved IMCIVREE® (setmelanotide) for the additional indication of weight management in adult and pediat

Yahoo · Sep 11, 2026

Billionaire Stanley Druckenmiller’s 2 New Healthcare Stock Picks

Stanley Druckenmiller’s Duquesne Family Office recently filed its 13F for the second quarter. The firm opened new stakes in more than 40 stocks. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) and Definium Therapeutics, Inc. (NASDAQ:DFTX) are the notable ones in the healthcare space. Duquesne bought 203,618 shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) worth $22.6 million. The fund also […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By